{
    "2019-10-08": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Pfizer (PFE) Stock Moves -1.1%: What You Should Know",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock Moves",
                        "-1.1%"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Were Hedge Funds Right About Souring on Pfizer?",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "Souring",
                        "Pfizer"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-17",
                "original_text": "5 Underperforming Guru Stocks",
                "features": {
                    "keywords": [
                        "Underperforming",
                        "Guru Stocks"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-18",
                "original_text": "Is Pfizer (NYSE:PFE) A Risky Investment?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Risky Investment"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-19",
                "original_text": "REFILE-UPDATE 1-Humira, Rituxan top list of U.S. drugs with biggest price increases -report",
                "features": {
                    "keywords": [
                        "Humira",
                        "Rituxan",
                        "price increases"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-20",
                "original_text": "REFILE-Humira, Rituxan top list of U.S. costliest drug price increases -report",
                "features": {
                    "keywords": [
                        "Humira",
                        "Rituxan",
                        "costliest drug",
                        "price increases"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}